IceCure Medical Ltd.

Snapshot

IceCure is a micro-cap medical device company burning cash much faster than it earns it. FY 2025 revenue was $3.4M but the company posted a $15.1M net loss, largely due to R&D spending that is more than double its total sales.

What's Happening Right Now

• Wed 17th Jun '26 · Financing: IceCure raised $5.5M in a private placement priced at $3.00 per share with a single institutional investor, issuing warrants alongside the shares.
• Wed 17th Jun '26 · Commercial: The company reported a 70% increase in its US active commercial install base for the ProSense system following FDA clearance and updated clinical guidelines.
• Tue 2nd Jun '26 · Corporate Action: IceCure announced a 1-for-30 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, reducing outstanding shares from about 84.2 million to 2.8 million.
• Tue 19th May '26 · Clinical Data: Data presented at ECIO 2026 showed an 89.4% recurrence-free rate for kidney cancer patients treated with ProSense, supporting broader commercial adoption.
• Thu 14th May '26 · Regulatory: Nasdaq granted IceCure a 180-day extension to regain compliance with the minimum bid price requirement, pushing the deadline to November 9, 2026.